and non-wear times was set at 25°C. Timeframes during which the temperature rose above 25°C were classified as wear time. A Wilcoxon signed-rank test was performed between the different wear times and Spearman's correlations between pain, comfort and wear time were determined. Results: On average, patients wore the device for 143±80 h according to the form they filled out, whereas the TS measured only 83±86 h, leading to an overestimation of 72%. Patients reported an average pain level of 3±1.4 during the six weeks period and the AFO's comfort was rated with 1.9±0.3. Statistical differences were found between the wear time reported by the patients and the wear time derived from the TS (p=0.005). Additionally, a significant correlation between the AFO comfort and the wear time derived from the TS was found (r = -0.81; p=0.001). No significant correlation was found between pain and wear time.
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and non-wear times was set at 25°C. Timeframes during which the temperature rose above 25°C were classified as wear time. A Wilcoxon signed-rank test was performed between the different wear times and Spearman's correlations between pain, comfort and wear time were determined. Results: On average, patients wore the device for 143±80 h according to the form they filled out, whereas the TS measured only 83±86 h, leading to an overestimation of 72%. Patients reported an average pain level of 3±1.4 during the six weeks period and the AFO's comfort was rated with 1.9±0.3. Statistical differences were found between the wear time reported by the patients and the wear time derived from the TS (p=0.005). Additionally, a significant correlation between the AFO comfort and the wear time derived from the TS was found (r = -0.81; p=0.001). No significant correlation was found between pain and wear time.
Conclusions: As can be expected, patients who found the AFO more comfortable were the ones who wore the orthosis for longer periods. The wear time recorded by the TS was significantly lower compared to the self-reports. This might be due to a social desire bias, overestimating the amount of hours of wearing the AFO as we asked the patients to wear it as often as possible. Secondly, patients might have trouble to accurately recall the amount of wear hours, thereby inducing an overestimation of wear time. As the reliability of self-reported measures seems to be questionable, such data should be interpreted with care. Background: Osteoarthritis and soft tissue pathology are diseases that produce important pain and disability in many patients. Some studies support that the low-dose radiotherapy may be effective in refractory diseases. Objectives: The main objective of this study is to evaluate whether the treatment with radiotherapy is long-term effective to reduce the pain in osteoarthritis and soft tissue pathology. The secondary objective is to evaluate the analgesic requirements before and after the treatment. Methods: A prospective and observational study was designed. 38 patients were included. 53 different pathologies were treated including knee osteoarthritis, trochanteric bursitis, calcinosis, rizartrosis, pyramidal syndrome, rotatory cuff pathology and shoulder osteoarthritis, plantar fasciitis, epicondylitis, hand osteoarthritis, tibialis posterior tendonitis, ankle osteoarthritis, hip osteoarthritis and hand tendonitis. All these pathologies did not respond to conventional therapy (non steroidal antiinflamatory drugs, rehabilitation or infiltrations). Initially, the patients received a treatment of radiotherapy with a dose of 6 Gray divided in 6 sessions during 2 weeks. The patients that did not respond after 6 weeks received a second treatment with the same characteristics. The modification in Visual Analogic Scale (VAS) of pain was evaluated as well as analgesic intake before and after the treatment. Results: No side effects were observed. 92% were women and 8% men. Mean age was 66,82, standard deviation (SD): 12,97 (42-89). 44 locations responded to one treatment and 19 needed a second one. The mean VAS prior treatment was 7,38, SD: 1,49, (10-4). Mean VAS after the first treatment was 3,81 SD: 2,84 (9-0). The mean VAS after the first treatment in locations that received 2 treatments was 6,65 SD: 1,46 (9-5), and mean VAS after the second one was 4,56 DE: 2,66 (8-1). By pathology, the difference in means was: 4,8 in knee osteoarthritis (N=11), 4,78 in trochanteric bursitis (N=10), 5 in calcinosis (N=3), 5,33 rizartrosis (N=8), 4 in pyramidal syndrome (N=2), 3,87 in rotatory cuff pathology and shoulder osteoarthritis (N=6), 6 in plantar fasciitis (N=1), 7 in epicondylitis (N=1), 3,22 in hand osteoarthritis (N=11), 6 in tibialis posterior tendonitis (N=2), 4 in ankle osteoarthritis (N=2), 2 in hip osteoarthritis (N=1) and 2,2 in hand tendonitis (N=5). Until November 2016, 12 patients (17 pathologies) were followed-up for 6 months. The mean VAS before treatment of these pathologies was 7,29 SD: 1,21; (9-4). After 6 months mean VAS reduced to 1,47 SD: 1,42; (5-0).
The analgesic intake was reduced in 37,98% of patients, 10,34% used the same amount and 34,48% was not known. 17,24% did not take analgesic drugs at all after treatment. Conclusions: The treatment with low dose radiotherapy was long-term effective for reducing the pain level in our study. Background: Epidemiological studies of ours and other groups have reported an inverse association between dietary and serum Mg with knee radiographic osteoarthritis (OA) [1] [2] [3] [4] . Objectives: To investigate the effects of dietary magnesium supplementation and intra-articular MgSO 4 on the development of experimental rat osteoarthritis, and explore the underlying potential molecular mechanisms by mRNA and lncRNA expression profiles screening. Methods: Rat osteoarthritis model was induced by surgery. Articular cartilage damage was evaluated by modified Mankin score system after intervention of dietary magnesium supplementation or intra-articular MgSO 4 injection. Microarray was performed to reveal alteration of expression profiles of mRNA and lncRNA after intervention of MgSO 4 on human osteoarthritis chondrocytes. Bioinformatics analyses including gene ontology analysis, pathway analysis, target gene predictions and network analysis were used. Results: Comparing with normal diet, dietary Mg supplementation showed significantly ameliorated cartilage damage at the medial femoral condyle, lateral tibial plateau and medial tibial plateau (P≤0.05), and approaching significance at the lateral femoral condyle (P=0.06). All four locations exhibited mitigated cartilage damage in the intra-articular MgSO 4 group compared with intra-articular saline (P≤0.05). 1767 lncRNAs and 2558 mRNAs were upregulated while 994 lncRNAs and 1512 mRNAs were downregulated in chondrocytes with intervention of 50mM MgSO4 compared with control group (fold change ≥2.0). The top 6 lncRNAs which showed the largest difference were ENST00000425914.2, ENST00000419881.1, ENST00000561231.1, ENST00000609062.1, TCONS_00029212 and ENST00000429530.1. Bioinformatics analyses indicated that the differentially expressed lncRNA target genes of chondrocyte after intervention of 50mM MgSO 4 are enriched in negative regulation of phosphatidylinositol 3-kinase signaling. Conclusions: Both dietary magnesium supplementation and intra-articular MgSO 4 injection may exert cartilage protective effects by causing widespread changes in the profile of lncRNAs and mRNAs of chondrocytes. 
